Lee Kalowski

Lee Kalowski, President and Chief Financial Officer of Q32 Bio, brings more than 20 years of biopharmaceutical experience with a focus on strategy, raising capital, and financial operations. Prior to his current role, Lee served as the Interim Chief Financial Officer of Q32 Bio. Before that, Lee was with Bicycle Therapeutics from 2017-2023, where he served as President and Chief Financial Officer, leading strategic finance and operations to support the company’s transition to a public clinical-stage biotech company. While at Bicycle, Lee helped raise $1 billion in capital, consisting of over $700 million in private, public, and non-dilutive financings including the company’s 2019 IPO and all subsequent financings. Prior to Bicycle, Lee was Chief Financial Officer of Tokai Pharmaceuticals where he helped lead the company’s IPO in 2014. Prior to Tokai, Lee served in global biotechnology equity research as a Senior Analyst at Credit Suisse, where he covered companies in the biopharmaceutical industry. Lee received a B.A. in biology and economics from Union College and an M.B.A. from The Wharton School of the University of Pennsylvania. Lee currently sits on the board of Aro Biotherapeutics.